The obesity–heart failure connection is particularly relevant, as obesity independently contributes to diastolic dysfunction, inflammation, and adverse cardiac remodeling [3,4,5,6,7,8,9,57,58]—all targets of GLP-1 RA therapy. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.